$SAFE

Goldman Sachs cuts Safehold stock price target on higher discount rate

Goldman Sachs reduced its price target for Safehold (SAFE) to $19 from $24, citing higher U.S. Treasury yields. The stock trades near its 52-week low, offering potential upside. Safehold's Q2 earnings met profit forecasts and exceeded revenue expectations. Multiple analysts have adjusted their outlooks, with mixed ratings and price targets.

Original reporting
Published Oct 21, 2026, 8:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$SAFE
Neutral
medium confidence
Mentioned
$SAFE
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SAFENeutralMed
01

Why it matters

Goldman’s target reduction is explicitly tied to a higher 30-year Treasury yield and an increased discount rate, which can shift valuation expectations for SAFE even without new company-specific operating news.

02

Market read

Traders may adjust valuation expectations for SAFE based on long-end yield sensitivity, while still weighing that the Street rating remains Buy.

03

What to watch

The article references recent earnings alignment and financing volatility concerns from other analysts, which could matter more than the discount-rate math for near-term trading.

Relevance 6/10Novelty 5/10Timing: after-hours/overnight analyst note, before next trading session

Background

Safehold is a ground-lease REIT whose valuation is sensitive to long-term interest rates via discounted cash-flow assumptions.

Company-level read

Ticker impact

$SAFENeutralMedium confidence
Context

Goldman Sachs cut Safehold’s price target to $19 from $24 while citing a higher 30-year Treasury yield and a higher discount rate.

Expected impact

Likely mild downside or capped upside as the market digests the lower target tied to higher discount-rate inputs.

Evidence & confidence

The article’s actionable change is the analyst price-target reduction driven by a specific rate assumption change, not a new operational shock.

Market effects

Reinforces that rate-sensitive real-estate cash-flow models for ground-lease REITs can re-rate with long-end yields.

US long-end yield move is the key driver, so broader REIT/real-estate sentiment may be affected.

Limited, as the catalyst is US Treasury yield-linked discounting.

Counterpoint

The Buy rating and low P/E framing suggest the target cut may be more about model inputs than deteriorating fundamentals.

Key entities

  • Safehold

    Subject of the analyst price-target cut and Buy rating maintained.

  • Goldman Sachs

    Lowered SAFE’s price target and adjusted the discount-rate assumption.

  • Caitlin Burrows

    Cited the higher 30-year Treasury yield and the discount-rate change.

Related articles

$SAFEMed

Safehold (SAFE): Higher Rates Test the Value of Its Long-Duration Ground-Lease Model

Safehold Inc. (SAFE) reported strong origination activity but faced caution from analysts like JPMorgan, which downgraded the stock to Underweight with a $14 price target. Concerns center on the company's low-yield, long-duration ground-lease model amid rising interest rates. Safehold defended its strategy, highlighting contractual rent growth and CPI-based escalators. The company also addressed leverage concerns through capital raises and extended debt maturities.

$SAFEMed

Press Release Safehold Reports Second Quarter 20 26 Results NEW…

Safehold Inc. (SAFE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 1114 Avenue of the Americas New York , NY 10036 T 212 .930 .9400 E investors@safeholdinc.com Press Release Safehold Reports Second Quarter 20 26 Results NEW YORK, July 30 , 20 26 Safehold Inc. ( NYSE: SAFE) reported results for the second quarter 20 26. SAFE publishe

$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.